CLINICAL TRIALS PROFILE FOR FINAFLOXACIN
✉ Email this page to a colleague
All Clinical Trials for FINAFLOXACIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00483158 ↗ | First Time in Man Study of Finafloxacin Hydrochloride | Completed | MerLion Pharmaceuticals GmbH | Phase 1 | 2007-08-01 | The purpose of this study is to study the safety of single doses and multiple doses of Finafloxacin hydrochloride in healthy volunteers. The level of Finafloxacin hydrochloride will be measured in the subjects blood and urine. One part of the study will assess if Finafloxacin hydrochloride eradicates Helicobacter pylori, a stomach bacteria. Another part of the study will assess the activity of the drug in urine. |
| NCT00722735 ↗ | Finafloxacin 300 mg Twice a Day (b.i.d.) Versus Ciprofloxacin 250 mg Twice a Day (b.i.d) in Patients With Lower Uncomplicated UTI (uUTI) | Completed | MerLion Pharmaceuticals GmbH | Phase 2 | 2008-10-01 | To compare the bacteriological eradication rates of Finafloxacin and Ciprofloxacin in female patients with uUTI. |
| NCT00723502 ↗ | Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients | Completed | MerLion Pharmaceuticals GmbH | Phase 2 | 2008-09-01 | The primary objective of this study is to compare the H. pylori eradication rates with Finafloxacin in combination with Amoxicillin or Esomeprazole. The secondary objective is to evaluate and compare the safety and tolerability of multiple oral doses of Finafloxacin plus Amoxicillin versus Finafloxacin plus Esomeprazole. |
| NCT01904162 ↗ | Effect of Age and Gender on the PK and Tolerability of Finafloxacin | Completed | MerLion Pharmaceuticals GmbH | Phase 1 | 2010-02-01 | Previous clinical studies have indicated that finafloxacin is well-tolerated with few treatment-related adverse events. As a part of the clinical development of finafloxacin, other PK studies are required to determine the effect of other variables on the PK profile of finafloxacin. This study aims to determine the effect of age and gender on the pharmacokinetic profile of finafloxacin. |
| NCT01907867 ↗ | Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin | Completed | MerLion Pharmaceuticals GmbH | Phase 1 | 2012-01-01 | This study investigates the safety, tolerability, and PK profile of finafloxacin as a novel fluoroquinolone and a potential therapeutic agent for lower respiratory infections such as bacterial pneumonia. A comparison of the PK profile of finafloxacin in plasma and lung ELF using different bronchoscopic ELF sampling techniques (BMS and BAL) is conducted. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for FINAFLOXACIN
Condition Name
Clinical Trial Locations for FINAFLOXACIN
Trials by Country
Clinical Trial Progress for FINAFLOXACIN
Clinical Trial Phase
Clinical Trial Sponsors for FINAFLOXACIN
Sponsor Name
